Lupin to set up two R&D centres in US
The R&D centres would focus on research in inhalation and complex formulations.
Mumbai, July 6, 2014: The Indian pharma firm Lupin is planning to set up two new R&D centres in the US focusing on research in inhalation and complex formulations.
"In keeping with our global strategy of building a highly differentiated generic and speciality business, the company is in the process to setting up two dedicated Centres of Excellence for research in inhalation and complex injectables in Florida and Maryland in the US," said Desh Bandhu Gupta, Chairman, Lupin in its annual report.
The company has increased its R&D spend to Rs 958.28 crore in FY14 from Rs 770.85 crore in FY13. "Lupin continues to invest heavily in its R&D programmes and in FY 2014, the company invested 8.6 per cent of its net sales in R&D and related spends, amounting to Rs 958.30 crore," said Gupta.
The company invested close to 8.1 per cent of its net sales in R&D and related spends amounting to Rs 770.85 crore in FY13.
The company already has reaped rich returns from its increased R&D spending. For instance, FY14 was a productive year for the pharma research group with 45 approvals in key advanced markets including 22 and one Supplemental NDA in the US, 10 in the EU, six in Australia, five in Canada and two in Japan.
The company has filed 19 ANDAs with the USFDA and four MAAs with the European regulators. It may be noted here that out of the 19 ANDAs filed with the USFDA, four are potential first-to-file.